News & Updates

Show Multimedia Only

ChatGPT holds promise as supplementary tool in clinical pharmacy

30 Jan 2024

Use of chat generative pretrained transformer (ChatGPT) can be of help among clinical pharmacists, but its capacity to handle complex problems needs to be improved and refined, suggests a study.

ChatGPT holds promise as supplementary tool in clinical pharmacy

30 Jan 2024

Rusfertide stabilizes haematocrit for 2.5 years in PCV

29 Jan 2024 by

The hepcidin mimetic rusfertide provides long-term control of haematocrit (2.5 years) and reduces the use of phlebotomy among patients with polycythemia vera (PCV) in the phase II REVIVE study

Rusfertide stabilizes haematocrit for 2.5 years in PCV

29 Jan 2024

TDM offers benefits in thiopurine-treated children with leukaemia, IBD

29 Jan 2024

Therapeutic drug monitoring (TDM) helps identify children treated by thiopurine for acute lymphoblastic leukaemia (ALL) and inflammatory bowel disease (IBD) who have not reached their target levels or are over treated, reports a recent study.

TDM offers benefits in thiopurine-treated children with leukaemia, IBD

29 Jan 2024

$Durable responses seen with axatilimab in recurrent/refractory GVHD$

Durable responses seen with axatilimab in recurrent/refractory GVHD

29 Jan 2024 by

The anti–CSF-R1 antibody axatilimab offers rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (GVHD) in the pivotal phase II AGAVE-201 trial.

Durable responses seen with axatilimab in recurrent/refractory GVHD

29 Jan 2024

One-time ceftriaxone cuts ventilator-associated pneumonia risk

28 Jan 2024

A single dose of ceftriaxone appears to reduce the risk of developing early ventilator-associated pneumonia (VAP) in patients with acute brain injury, according to the PROPHY-VAP study.

One-time ceftriaxone cuts ventilator-associated pneumonia risk

28 Jan 2024

Long-term steroid-free pemphigus remission achieved with frontline rituximab

28 Jan 2024 by

First-line treatment with rituximab appears to induce durable remission in patients with pemphigus, and this is achieved without corticosteroid therapy and any additional maintenance infusion of rituximab.

Long-term steroid-free pemphigus remission achieved with frontline rituximab

28 Jan 2024

Biologics effective, safe for inflammatory conditions of the pouch

28 Jan 2024

Use of biologics provides clinical benefits in patients with chronic, refractory inflammatory conditions of the pouch, with no new safety signals observed, reports a study. Moreover, infliximab appears more effective than adalimumab and vedolizumab for chronic antibiotic-refractory pouchitis (CARP).

Biologics effective, safe for inflammatory conditions of the pouch

28 Jan 2024

Exhalation delivery system with fluticasone passes muster in two chronic rhinosinusitis trials

27 Jan 2024 by

In the treatment of chronic rhinosinusitis (CRS), exhalation delivery system with fluticasone (EDS-FLU) provides relief from symptoms while reducing intrasinus disease and the incidence of acute exacerbations, regardless of the presence of polyps, as shown in the phase III trials ReOpen1 and ReOpen2.

Exhalation delivery system with fluticasone passes muster in two chronic rhinosinusitis trials

27 Jan 2024

Clinical outcomes vary among older adults taking antidepressants

27 Jan 2024

Use of commonly used antidepressants may result in different outcomes among older adults initiating this medication for depression, as shown in a study.

Clinical outcomes vary among older adults taking antidepressants

27 Jan 2024

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

27 Jan 2024

Combining the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab appears to be efficacious and safe in the second-line treatment of metastatic esophagogastric adenocarcinoma, as shown in the phase II nonrandomized RAP trial.

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

27 Jan 2024

News & Updates

Showing Pharmacy articles

Showing

Specialty:

ChatGPT holds promise as supplementary tool in clinical pharmacy

ChatGPT holds promise as supplementary tool in clinical pharmacy

Rusfertide stabilizes haematocrit for 2.5 years in PCV

Rusfertide stabilizes haematocrit for 2.5 years in PCV

TDM offers benefits in thiopurine-treated children with leukaemia, IBD

TDM offers benefits in thiopurine-treated children with leukaemia, IBD

Durable responses seen with axatilimab in recurrent/refractory GVHD

Durable responses seen with axatilimab in recurrent/refractory GVHD

One-time ceftriaxone cuts ventilator-associated pneumonia risk

One-time ceftriaxone cuts ventilator-associated pneumonia risk

Long-term steroid-free pemphigus remission achieved with frontline rituximab

Long-term steroid-free pemphigus remission achieved with frontline rituximab

Biologics effective, safe for inflammatory conditions of the pouch

Biologics effective, safe for inflammatory conditions of the pouch

Exhalation delivery system with fluticasone passes muster in two chronic rhinosinusitis trials

Exhalation delivery system with fluticasone passes muster in two chronic rhinosinusitis trials

Clinical outcomes vary among older adults taking antidepressants

Clinical outcomes vary among older adults taking antidepressants

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma